Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3016 | Pneumococcal Conjugate Vaccine - formulation 1 Wiki | 1.00 |
| drug4046 | Tracheotomy Wiki | 1.00 |
| drug3018 | Pneumococcal Conjugate Vaccine - formulation 3 Wiki | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
Primary Objective: - To assess the immune response of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23 30 days after the administration of the single dose vaccination - To assess the safety profile of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23
Description: Serotype specific OPA titers for all pneumococcal serotypes included in the SP0202 formulations are determined
Measure: Geometric Mean (GM) of serotype specific opsonophagocytic (OPA) titers for all pneumococcal serotypes included in the SP0202 formulations Time: Day 31Description: Serotype specific OPA titers for all pneumococcal serotypes included in the SP0202 formulations are determined The calculated ratio is (post/pre-vaccination)
Measure: GM of serotype specific OPA titers ratio for all pneumococcal serotype included in the SP0202 formulations Time: Day 31Description: Ab concentrations for all pneumococcal serotypes included in the SP0202 formulations are measured
Measure: Geometric Mean Concentrations (GMCs) of antibodies against all pneumococcal serotypes included in the SP0202 formulations Time: Day 31Description: Ab concentrations for all pneumococcal serotypes included in the SP0202 formulations are measured The calculated ratio is (post-/pre-vaccination)
Measure: Geometric Mean Concentrations Ratio (GMCR) of antibodies against all pneumococcal serotypes included in the SP0202 formulations Time: Day 31Description: Unsolicited (spontaneously reported) systemic AEs after vaccination with a SP0202 formulation, Prevnar 13 or Pneumovax 23
Measure: Number of participants reporting immediate adverse events (AEs) Time: Within 30 minutes post-vaccinationDescription: Solicited injection site and systemic reactions after vaccination with a SP0202 formulation, Prevnar 13 or Pneumovax 23 Solicited injection site reactions: pain, erythema, swelling Solicited systematic reactions: fever, headache, malaise, myalgia, arthralgia, shivering
Measure: Number of participants reporting solicited injection site and systemic reactions Time: Up to Day 8Description: Unsolicited AEs (events not solicited) after vaccination with a SP0202 formulation, Prevnar 13 or Pneumovax 23
Measure: Number of participants reporting unsolicited (spontaneously reported) AEs Time: Up to Day 31Description: SAEs and AESIs are collected throughout the study period
Measure: Number of participants reporting serious adverse events (SAEs) and adverse events of special interest (AESIs) Time: Up to Day 181Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports